Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Potent and selective ETA antagonist from SKB

April 16, 1997

CVT-124 enters phase II trials for CHF

April 16, 1997

Meiji Seika discloses new cardiotonic agents

April 16, 1997

Takeda reveals endothelin antagonists

April 14, 1997

FR-138104: a new D2 antagonist from Fujisawa

April 10, 1997

Lederle (Japan) reports novel cardioprotective agents

April 10, 1997

SmithKline Beecham claims novel endothelin antagonists

April 9, 1997

AMBI's Cardia Salt Alternative associated with reduced blood pressure

April 9, 1997

Component of olive oil demonstrates antioxidant and lipoxygenase-inhibitory effects

April 8, 1997

Transmyocardial Revascularization phase II results reported

April 7, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...